The annual J.P. Morgan Healthcare Conference convenes thousands of healthcare investors, global industry leaders and technology innovators to explore the key trends shaping the industry in 2026 and beyond. If you would ...
In the News
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Investing in Anti-HIV: How Anti-HIV Therapeutic Developers Can Reshape the Future of HIV Control
Despite decades of progress transforming HIV from a fatal diagnosis into a manageable chronic condition, today’s antiretroviral therapies still face a stubborn barrier: They work brilliantly in theory but fall short when access, adherence, and real-world challenges get in the way.
-
Multidrug-Resistant Infections Necessitate Bacteriophage Treatment: Can We Get There in Time?
As antibiotic resistance surges globally, bacteriophage therapy is emerging as a promising alternative for treating multidrug-resistant infections. To scale this life-saving approach, investment in phage development, clinical trials, and diagnostic infrastructure is urgently needed.
-
Early-phase study design considerations for long-term follow-up in vaccine clinical trials
ICON experts discuss why strategic early planning is key to long-term follow-up in vaccine trials—driving stronger protocols, regulatory alignment, and meaningful outcomes.
-
Hot shots: The power and potential of study tokenisation for vaccine research and post-commercialisation
Discover how clinical trial tokenisation helps sponsors gain patient insights and enable long-term data collection—without adding burden to patients or sites.
-
Overcoming challenges with maternal vaccine trials
In this article from pharmaphorum, Dinah Knotts, VP of Project Management in Vaccines and Infectious Diseases and Mitsu Rana, Senior Director of Project Management outline some of the challenges with maternal vaccine trials and how with careful planning and execution by researchers, these can be overcome throughout the trial process.
-
Decoding pandemic precision: From SARS-CoV-2 to influenza vaccination strategies
The need for public health officials to be able to model the spread of infectious diseases has never been more apparent than in the early days of the SARS-CoV-2 pandemic, but what needs to change? Read the article by ICON epidemiologist Dr. Richard Pitman in Open Access Government.
-
Logistical considerations in mRNA vaccine development
In this article, ICON’s Andreas Dreps and Martin Lachs discuss the logistical considerations in mRNA vaccine development.
©BioPharm International
-
ICON partners with US Government for clinical trials of Covid-19 vaccines
The article on Clinical Trials Arena reports that ICON will conduct a phase 2b clinical trial for the US BARDA-selected Covid-19 vaccine candidate as part of Project NextGen.
-
BARDA, ICON partner to execute next-gen COVID vaccine trial
This news article from Contract Pharma reports that ICON will execute a Phase 2b clinical trial to assess the relative efficacy of a next generation COVID-19 vaccine.
-
ICON in pact with BARDA for next-gen COVID vaccine trial
The piece from Seeking Alpha highlights that the trial is designed to evaluate the vaccine candidate selected by BARDA, which functions as part of the Administration for Strategic Preparedness and Response under the U.S. Department of Health and Human Services.
